Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 14/20 | 0.80 |
| ▸ | HDAC4 | P56524 | 14/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.80 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.80 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 0.80 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.80 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.80 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 0.80 |
| ▸ | EGFR | P00533 | 13/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.79 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642808 | 0.89 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL642252 | 0.88 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL642768 | 0.88 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL642881 | 0.86 | EGFR (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL16199852 | 0.85 | HDAC6 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8211781 | 0.83 | HDAC3 (0.83) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8216606 | 0.83 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8213639 | 0.81 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL641658 | 0.79 | HDAC3 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8203950 | 0.79 | EGFR (0.98) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190287-B1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2009035718-A1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC6, HDAC5, HDAC1 | HDAC3 12/4885HDAC4 5/4885HDAC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.